Zarifkar Pardis, Peinkhofer Costanza, Benros Michael E, Kondziella Daniel
Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Copenhagen Research Center for Mental Health-CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Front Neurol. 2022 Jun 23;13:904796. doi: 10.3389/fneur.2022.904796. eCollection 2022.
COVID-19 might affect the incidence of specific neurological diseases, but it is unknown if this differs from the risk following other infections. Here, we characterized the frequency of neurodegenerative, cerebrovascular, and immune-mediated neurological diseases after COVID-19 compared to individuals without COVID-19 and those with other respiratory tract infections.
This population-based cohort study utilized electronic health records covering ~50% of Denmark's population ( = 2,972,192). Between 02/2020 and 11/2021, we included individuals tested for COVID-19 or diagnosed with community-acquired bacterial pneumonia in hospital-based facilities. Additionally, we included individuals tested for influenza in the corresponding pre-pandemic period between 02/ 2018 and 11/2019. We stratified cohorts for in- and outpatient status, age, sex, and comorbidities.
In total, 919,731 individuals were tested for COVID-19, of whom 43,375 tested positive (35,362 outpatients, 8,013 inpatients). Compared to COVID-negative outpatients, COVID-19 positive outpatients had an increased RR of Alzheimer's disease (RR = 3.5; 95%CI: 2.2-5.5) and Parkinson's disease (RR = 2.6; 95%CI: 1.7-4.0), ischemic stroke (RR = 2.7; 95%CI: 2.3-3.2) and intracerebral hemorrhage (RR = 4.8; 95%CI: 1.8-12.9). However, when comparing to other respiratory tract infections, only the RR for ischemic stroke was increased among inpatients with COVID-19 when comparing to inpatients with influenza (RR = 1.7; 95%CI: 1.2-2.4) and only for those >80 years of age when comparing to inpatients with bacterial pneumonia (RR = 2.7; 95%CI: 1.2-6.2). Frequencies of multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome and narcolepsy did not differ after COVID-19, influenza and bacterial pneumonia.
The risk of neurodegenerative and cerebrovascular, but not neuroimmune, disorders was increased among COVID-19 positive outpatients compared to COVID-negative outpatients. However, except for ischemic stroke, most neurological disorders were not more frequent after COVID-19 than after other respiratory infections.
新型冠状病毒肺炎(COVID-19)可能会影响特定神经系统疾病的发病率,但与其他感染后的风险相比是否存在差异尚不清楚。在此,我们对COVID-19患者、未感染COVID-19的个体以及患有其他呼吸道感染的个体发生神经退行性疾病、脑血管疾病和免疫介导的神经系统疾病的频率进行了特征分析。
这项基于人群的队列研究利用了覆盖丹麦约50%人口(n = 2,972,192)的电子健康记录。在2020年2月至2021年11月期间,我们纳入了在医院设施中接受COVID-19检测或被诊断为社区获得性细菌性肺炎的个体。此外,我们纳入了在相应的大流行前时期(2018年2月至2019年11月)接受流感检测的个体。我们根据门诊和住院状态、年龄、性别和合并症对队列进行分层。
共有919,731人接受了COVID-19检测,其中43,375人检测呈阳性(35,362名门诊患者,8,013名住院患者)。与COVID-19阴性门诊患者相比,COVID-19阳性门诊患者患阿尔茨海默病(RR = 3.5;95%CI:2.2 - 5.5)、帕金森病(RR = 2.6;95%CI:1.7 - 4.0)、缺血性中风(RR = 2.